EQT Life Sciences Partners in Major Financing of SpliceBio
EQT Life Sciences has jointly led a remarkable $135 million Series B financing round in SpliceBio, a pioneering biotech company focused on innovative therapies for genetic disorders. Partnering with Sanofi Ventures, this financing round also welcomed contributions from Roche Venture Fund and various previous investors.
Support for Clinical Development of SB-007
The funds raised will significantly bolster the Phase 1/2 clinical trial for SB-007, SpliceBio's lead candidate aimed at treating Stargardt disease. This genetic eye disorder leads to substantial vision loss and, ultimately, blindness. Stargardt disease is characterized by progressive degeneration of the macula and affects approximately 1 in 8,000-10,000 individuals.
This financing reflects a concerted effort to not only provide resources for SB-007 but also to enhance SpliceBio’s expansive pipeline of genetic medicines focused on ophthalmology, neurology, and other crucial areas.
The Innovative Technology Behind SpliceBio
SpliceBio is leveraging a groundbreaking intein platform to develop therapies that tackle genetic diseases effectively. This platform facilitates splitting larger genes into manageable segments for easier delivery, making it feasible to construct full-length proteins required for treatment. The methodologies originate from advanced research initially established at a prominent university, enabling significant progress in therapeutic development.
SpliceBio's approach to treating Stargardt disease is unique as it targets the ABCA4 gene, which is notorious for its size and associated delivery complications in traditional gene therapy contexts. By using Protein Splicing technology, SpliceBio aims to produce healthy ABCA4 proteins directly in the retina, potentially addressing a wide range of mutations that cause the disease.
Future Implications and Broader Impact
This innovative therapy has implications far beyond Stargardt disease, addressing a common challenge in delivering treatment for various genetic disorders. The versatility of SpliceBio's technology bodes well for patients suffering from other conditions marked by similar complications, thus widening the impact of their research significantly.
Miquel Vila-Perelló, CEO and Co-Founder of SpliceBio, expressed his optimism regarding this financing, stating, "This is a pivotal milestone for our company as we continue progressing SB-007 for Stargardt disease while also expanding our horizons into new therapeutic areas." The support from prestigious investors stands testament to the strength and potential of SpliceBio's innovative platform.
Commitment from EQT Life Sciences
Daniela Begolo, Managing Director at EQT Life Sciences, also emphasized the firm’s commitment to SpliceBio, likening their Protein Splicing platform to a beacon of hope for patients facing untreatable genetic conditions. By investing in SpliceBio, EQT Life Sciences reaffirms its dedication to supporting solutions that can fundamentally change lives.
Frequently Asked Questions
What is the main objective of the financing round for SpliceBio?
The $135 million financing aims to support the clinical development of SB-007 for treating Stargardt disease and enhance a broad pipeline of genetic medicines.
Who co-led the financing round for SpliceBio?
The financing was co-led by EQT Life Sciences and Sanofi Ventures, along with participation from Roche Venture Fund and other existing investors.
What condition is SB-007 targeting?
SB-007 is specifically being developed to treat Stargardt disease, a genetic eye disorder that results in progressive vision loss.
What technology does SpliceBio utilize in its therapies?
SpliceBio employs an innovative intein platform that allows for the splitting and reassembly of large genes, facilitating gene therapy delivery.
What is the broader significance of SpliceBio's research?
The research and technology have the potential to address numerous genetic disorders, making it a key player in the evolving landscape of genetic medicine.
